TargetMol

Ruboxistaurin mesylate

Product Code:
 
TAR-T3689L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3689L-50mg50mg£768.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3689L-100mg100mg£1,123.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ruboxistaurin is a PKC beta inhibitor. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
CAS:
192050-59-2
Formula:
C29H32N4O6S
Molecular Weight:
564.66
Purity:
0.98
SMILES:
CS(O)(=O)=O.CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21

References

Schwartz SG, Flynn HW Jr, Aiello LP. Ruboxistaurin mesilate hydrate for diabetic retinopathy. Drugs Today (Barc). 2009 Apr;45(4):269-74. doi: 10.1358/dot.2009.45.4.1354195. Review. PubMed PMID: 19499092. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Nov;31(9):597-633. PubMed PMID: 20094643. Beckman JA, Goldfine AB, Goldin A, Prsic A, Kim S, Creager MA. Inhibition of protein kinase Cbeta does not improve endothelial function in type 2 diabetes. J Clin Endocrinol Metab. 2010 Aug;95(8):3783-7. doi: 10.1210/jc.2010-0286. Epub 2010 May 5. PubMed PMID: 20444914; PubMed Central PMCID: PMC2913029. Meier M, Menne J, Haller H. Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice. Diabetologia. 2009 May;52(5):765-75. doi: 10.1007/s00125-009-1278-y. Epub 2009 Feb 24. Review. PubMed PMID: 19238353.